PMC:7405836 / 101697-101998 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T3","span":{"begin":146,"end":150},"obj":"Body_part"},{"id":"T4","span":{"begin":227,"end":231},"obj":"Body_part"}],"attributes":[{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Therapeutic agents that have anti-SARS-CoV-2 activity can be broadly classified into three categories: drugs that block virus entry into the host cell, drugs that block viral replication as well as its survival within the host cell, and drugs that attenuate the exaggerated host immune response (300)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T917","span":{"begin":34,"end":42},"obj":"Disease"},{"id":"T918","span":{"begin":34,"end":38},"obj":"Disease"}],"attributes":[{"id":"A917","pred":"mondo_id","subj":"T917","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A918","pred":"mondo_id","subj":"T918","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Therapeutic agents that have anti-SARS-CoV-2 activity can be broadly classified into three categories: drugs that block virus entry into the host cell, drugs that block viral replication as well as its survival within the host cell, and drugs that attenuate the exaggerated host immune response (300)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T6","span":{"begin":45,"end":53},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T7","span":{"begin":120,"end":125},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T8","span":{"begin":146,"end":150},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T9","span":{"begin":227,"end":231},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"Therapeutic agents that have anti-SARS-CoV-2 activity can be broadly classified into three categories: drugs that block virus entry into the host cell, drugs that block viral replication as well as its survival within the host cell, and drugs that attenuate the exaggerated host immune response (300)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T29307","span":{"begin":103,"end":108},"obj":"Chemical"},{"id":"T17949","span":{"begin":152,"end":157},"obj":"Chemical"},{"id":"T45023","span":{"begin":237,"end":242},"obj":"Chemical"}],"attributes":[{"id":"A2853","pred":"chebi_id","subj":"T29307","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A5987","pred":"chebi_id","subj":"T17949","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A50025","pred":"chebi_id","subj":"T45023","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"Therapeutic agents that have anti-SARS-CoV-2 activity can be broadly classified into three categories: drugs that block virus entry into the host cell, drugs that block viral replication as well as its survival within the host cell, and drugs that attenuate the exaggerated host immune response (300)."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T3","span":{"begin":120,"end":150},"obj":"http://purl.obolibrary.org/obo/GO_0046718"},{"id":"T4","span":{"begin":169,"end":186},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T5","span":{"begin":169,"end":186},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T6","span":{"begin":279,"end":294},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"text":"Therapeutic agents that have anti-SARS-CoV-2 activity can be broadly classified into three categories: drugs that block virus entry into the host cell, drugs that block viral replication as well as its survival within the host cell, and drugs that attenuate the exaggerated host immune response (300)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T701","span":{"begin":0,"end":301},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Therapeutic agents that have anti-SARS-CoV-2 activity can be broadly classified into three categories: drugs that block virus entry into the host cell, drugs that block viral replication as well as its survival within the host cell, and drugs that attenuate the exaggerated host immune response (300)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2741","span":{"begin":34,"end":44},"obj":"Species"}],"attributes":[{"id":"A2741","pred":"tao:has_database_id","subj":"2741","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Therapeutic agents that have anti-SARS-CoV-2 activity can be broadly classified into three categories: drugs that block virus entry into the host cell, drugs that block viral replication as well as its survival within the host cell, and drugs that attenuate the exaggerated host immune response (300)."}